trending Market Intelligence /marketintelligence/en/news-insights/trending/e7by0OiJu8_imGFezBi3VQ2 content esgSubNav
In This List

Valeant's eye drops rejected by US FDA

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Valeant's eye drops rejected by US FDA

The U.S. Food and Drug Administration rejected Valeant Pharmaceuticals International Inc.'s investigative eye drops for patients with open angle glaucoma or ocular hypertension.

The complete response letter for latanoprostene bunod ophthalmic solution only refers to a current good manufacturing practice inspection at a Bausch & Lomb facility in Tampa, Fla.

The letter did not identify any efficacy or safety issues with the application for the eye drops or additional clinical trials needed for the approval of the application.

Valeant said it will work closely with the agency to determine the suitable next steps for the application.